(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
Live Chart Being Loaded With Signals
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions...
Stats | |
---|---|
本日の出来高 | 6.46M |
平均出来高 | 1.77M |
時価総額 | 833 204 |
EPS | $0 ( 2024-03-29 ) |
次の収益日 | ( $0 ) 2024-05-16 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.00818 |
ATR14 | $0.00600 (26.55%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-12-18 | Hansen Maia | Sell | 67 | Common Stock |
2023-10-04 | Hansen Maia | Sell | 23 149 | Common Stock |
2023-10-04 | Camardo Daniel A. | Sell | 19 993 | Common Stock |
2023-09-18 | Hansen Maia | Sell | 67 | Common Stock |
2023-08-17 | Mayhugh Neema | Buy | 27 428 | NonQualified Stock Option (right to purchase) |
INSIDER POWER |
---|
23.17 |
Last 94 transactions |
Buy: 8 476 520 | Sell: 1 272 175 |
ボリューム 相関
Athersys Inc 相関
10 最も負の相関 | |
---|---|
NVCN | -0.951 |
STAY | -0.929 |
TIOA | -0.926 |
AVEO | -0.924 |
VCXA | -0.921 |
XM | -0.92 |
PCRX | -0.919 |
BRIVU | -0.919 |
ITMR | -0.915 |
ENER | -0.914 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Athersys Inc 相関 - 通貨/商品
Athersys Inc 財務諸表
Annual | 2022 |
収益: | $5.33M |
総利益: | $5.33M (100.00 %) |
EPS: | $-5.70 |
FY | 2022 |
収益: | $5.33M |
総利益: | $5.33M (100.00 %) |
EPS: | $-5.70 |
FY | 2021 |
収益: | $5 514.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $0 |
FY | 2020 |
収益: | $1.44M |
総利益: | $1.44M (100.00 %) |
EPS: | $-0.420 |
Financial Reports:
No articles found.
Athersys Inc
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical needs. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。